Mode
Text Size
Log in / Sign up
N/A Completed N=44 Randomized Double-blind Treatment

Dispensing Study for a New Study Lens

Source: ClinicalTrials.gov NCT02642991 ↗
Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcomePrimary: Distance Visual Acuity (VA) - High Illumination — -0.10; -0.11; -0.15; -0.17 logMAR

Summary

This study investigated the performance criteria over one week of daily wear to determine if the comfilcon A asphere lens (test) performed equivalently to the comfilcon A sphere (control) in terms of measurement and subjective ratings of visual performance.

Outcome Measures

OutcomeResultp-value
PRIMARY
Distance Visual Acuity (VA) - High Illumination
-0.10; -0.11; -0.15; -0.16
PRIMARY
Distance Visual Acuity (VA) - High Illumination
-0.10; -0.11; -0.15; -0.16
PRIMARY
Near Visual Acuity (VA) - High Illumination
-0.06; -0.07; -0.11; -0.13
PRIMARY
Near Visual Acuity (VA) - High Illumination
-0.06; -0.07; -0.11; -0.13
PRIMARY
Distance Visual Acuity (VA) - Low Illumination
0.06; 0.05; -0.01; 0.01
PRIMARY
Distance Visual Acuity (VA) - Low Illumination
0.06; 0.05; -0.01; 0.01
PRIMARY
Near Visual Acuity (VA) - Low Illumination
0.16; 0.18; 0.09; 0.11
PRIMARY
Near Visual Acuity (VA) - Low Illumination
0.16; 0.18; 0.09; 0.11
PRIMARY
Quality of Distance Vision
87; 90
PRIMARY
Quality of Distance Vision
87; 90
PRIMARY
Quality of Near Vision
90; 90
PRIMARY
Quality of Near Vision
90; 90
PRIMARY
Quality of Vision With Digital Device Use
91; 90
PRIMARY
Quality of Vision With Digital Device Use
91; 90
PRIMARY
Quality of Intermediate Vision
92; 92
PRIMARY
Quality of Intermediate Vision
92; 92
PRIMARY
Overall Vision Quality
88; 89
PRIMARY
Overall Vision Quality
88; 89
SECONDARY
Biomicroscopy Findings - Bulbar Hyperemia
1.24; 1.37
SECONDARY
Biomicroscopy Findings- Limbal Hyperemia
0.98; 1.21
SECONDARY
Biomicroscopy Findings - Corneal Staining Extent
0.05; 0.10; 0.14; 0.16; 0.07; 0.03
SECONDARY
Ghosting - Distance Vision
93; 93
SECONDARY
Ghosting - Near Vision
93; 93
SECONDARY
Overall Comfort
78; 79
SECONDARY
Overall Comfort
78; 79
SECONDARY
Overall Dryness
76; 77
SECONDARY
Overall Dryness
76; 77
SECONDARY
Lens Preference - Overall Vision Preference
14; 25; 5
SECONDARY
Subjective Ratings of Change in Frequency of Tiredness
11; 18; 50; 39; 36; 39
SECONDARY
Subjective Ratings of Change in Severity of Tiredness
17; 17; 48; 39; 26; 35
SECONDARY
Subjective Ratings of Change in Bothersome Rating for Tiredness
20; 10; 45; 45; 35; 40
SECONDARY
Subjective Ratings of Change in Frequency of Dryness
15; 20; 35; 15; 25; 35
SECONDARY
Subjective Ratings of Change in Severity of Dryness
9; 5; 41; 41; 32; 27
SECONDARY
Subjective Ratings of Change in Bothersome Rating of Dryness
15; 10; 40; 40; 25; 25
SECONDARY
Subjective Questionnaire Response - Eye Strain
75; 75; 25; 25
SECONDARY
Subjective Questionnaire Response - Eye Feel Good
86; 71; 14; 29
SECONDARY
Subjective Questionnaire Response - Eye Feel Relaxed
79; 79; 21; 21
SECONDARY
Subjective Questionnaire Response - Vision
96; 96; 4; 4
SECONDARY
Subjective Questionnaire Response - Eye Tired
82; 75; 18; 25

Eligibility Criteria

Inclusion Criteria

A person is eligible for inclusion in the study if he/she:

  • Oculo-visual examination in the last two years
  • Between 18 and 35 years of age and has full legal capacity to volunteer
  • Has read and understood the informed consent letter
  • Is willing and able to follow instructions and maintain the appointment schedule
  • Is correctable to a visual acuity of 20/25 or better (in each eye) with their habitual correction or 20/20 best corrected
  • Currently wears, or has previously successfully worn, soft contact lenses between -1.00D (Diopoter) and -4.00D
  • Spherical Contact Lens Rx between -1.00 and -4.00 and spectacle cylinder 1.00
  • Has undergone corneal refractive surgery
  • Has strabismus
  • Has any ocular amblyopia >= 1line of HC (High Contrast) Visual Acuity
  • Is participating in any other type of eye related clinical or research study
  • Has previously participated in study of the Phenacite lenses
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02642991). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search